Ann: Investor Presentation, page-20

They received another 500k in the bank in January from option conversions.

So, they have $2.7 mil at 31 december plus $500k. I was told thats plenty to take them through to FDA approval.

They are under pressure though from several large investment groups to carry out a placement so that these groups don't have to chase on market. So far Directors have held strong and resisted.

I believe several funds have been buying since Christmas and hence why the share price has held up so well. The presentations they carried out in New York (including to Harvard University) went down very well. Won best new product at the pneumonia conference in New York. That says a lot.